- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02043002
Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Erlotinib, an anti-cancer agent targeting the epidermal growth factor receptor (EGFR), is an active treatment of patients with non-small cell lung cancer (NSCLC). Effect of treatment is primary seen in patients harboring a mutation in the EGFR. However, 10-15% of patients does not harbor a mutation but respond as well. Identifying these patients is a problem and methods are lacking.
Studies have shown that an early 18F FDG-PET might can predict response and outcome in these patients, but further studies are needed to confirm these findings.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jylland
-
Aarhus, Jylland, Denmark, 8000
- Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Lung Cancer patients with non-small cell histology and stage IV disease
- candidate for erlotinib treatment as first/ second/ third line of treatment
Exclusion Criteria:
- pregnancy
- severe dyspnoea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-FDG-PET scan
An early evaluation 18F-FDG-PET scan after 7-10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
18F-FDG-PET evaluation
Time Frame: Time to progression and latest april 2015 (up to 2 years)
|
Standardized Uptake Values (SUV) will be used as measurement of 18F-FDG uptake
|
Time to progression and latest april 2015 (up to 2 years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Thomas
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer Patients
-
BIND TherapeuticsCompletedSquamous Cell Non-small Cell Lung Cancer | KRAS Positive Patients With Non-small Cell Lung CancerUnited States, Russian Federation
-
Marc de PerrotOzmosis Research Inc.Not yet recruitingNon-small Cell Lung Cancer (NSCLC) | Lung Cancer Patients
-
Fondazione Ricerca TraslazionaleNot yet recruitingNon-small-cell Lung Cancer PatientsItaly
-
University of Turin, ItalyUnknownNon Small Cell Lung Cancer PatientsItaly
-
Fondazione Ricerca TraslazionaleRecruiting
-
Assistance Publique Hopitaux De MarseilleActive, not recruitingNon-small Cell Lung Cancer PatientsFrance
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityXijing Hospital; First Affiliated Hospital Xi'an Jiaotong University; Shanxi... and other collaboratorsUnknownPatients With Non-small Cell Lung CancerChina
-
AstraZenecaCompletedEGFR Mutated Non-small Cell Lung Cancer PatientsSpain
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Shanghai Chest HospitalNot yet recruitingCardiac Event | Immune Checkpoint Inhibitor | Adverse Reactions | Non-Small Cell Lung Cancer Patients
Clinical Trials on 18F-FDG-PET scan
-
Tim LauMcGill UniversityNot yet recruitingCognitive Impairment | Dementia | Dementia With Lewy Bodies
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
Duke UniversityRecruitingEsophageal Cancer | Vulvar Cancer | Anal Canal Cancer | Cancer of the CervixUnited States
-
University of OklahomaMidwest Medical IsotopesTerminatedNon-Hodgkin's LymphomaUnited States
-
University of UtahTerminatedAlzheimer's DiseaseUnited States
-
Hospices Civils de LyonCompleted
-
University of PennsylvaniaCompleted
-
Jules Bordet InstituteCompletedColorectal Cancer Metastatic | Early Response Evaluation | Fdg-PETBelgium